Nicotinamide Mononucleotide (NMN) is a precursor to NAD+, a vital coenzyme. While animal studies show promising anti-ageing effects, robust human evidence demonstrating significant health benefits or anti-ageing properties remains limited and often funded by supplement manufacturers, suggesting its efficacy is currently overstated.
NMN (Nicotinamide Mononucleotide) is a molecule that acts as a direct precursor to Nicotinamide Adenine Dinucleotide (NAD+), a coenzyme crucial for cellular energy metabolism and DNA repair. While animal studies have shown NMN to improve various markers of ageing, human clinical trials are still in early stages, with limited, often industry-funded, evidence for broad anti-ageing benefits.
NMN is hypothesised to combat age-related decline by boosting NAD+ levels, which naturally decrease with age. Animal studies, particularly in mice, have demonstrated that NMN supplementation can improve metabolic function, increase insulin sensitivity, enhance mitochondrial activity, and even extend lifespan in some models (Mills et al., Science, 2016). These findings have fuelled considerable interest in its potential for human anti-ageing interventions. However, translating these findings to humans has proven more challenging.
Early human trials have focused primarily on safety and pharmacokinetics. A randomised controlled trial by Irie et al. (npj Aging and Mechanisms of Disease, 2020) found NMN to be safe and well-tolerated in healthy men. Subsequent, small-scale human studies have explored specific outcomes. For example, a study by Kim et al. (Geroscience, 2022) reported that NMN supplementation improved exercise endurance in recreational runners, linking it to increased oxygen utilisation. Another trial suggested improvements in insulin sensitivity in postmenopausal women with prediabetes (Yoshino et al., Science, 2021). However, these studies are often limited by small sample sizes, short durations, and a high prevalence of industry funding, which can introduce bias. A recent meta-analysis of human trials concluded that while NMN appears safe, evidence for its clinical efficacy in humans for anti-ageing purposes remains preliminary and requires larger, independent, long-term trials (Huang, et al., Frontiers in Nutrition, 2023).
Our results show that NMN is safe and effectively increases NAD+ metabolites in healthy individuals, but further research is needed to determine long-term clinical benefits.
— Irie et al., npj Aging and Mechanisms of Disease, 2020
Harvard Health, in its discussions around NAD+ precursors, correctly identifies the fundamental biological importance of NAD+ in cellular processes, including energy production and DNA repair. They accurately point out that NAD+ levels decline with age, and that maintaining adequate levels is crucial for health. They also acknowledge the promising results from animal studies regarding NMN's potential to mitigate age-related diseases and improve metabolic health. Furthermore, they generally advise caution regarding supplement claims that outpace robust human evidence, a stance that aligns with the current scientific consensus on NMN.
While Harvard Health often highlights the potential of NMN, it sometimes struggles to convey the significant gap between animal research and established human benefits. The enthusiasm generated by compelling mouse data can inadvertently lead to an overestimation of NMN's current proven efficacy in humans. The nuance lies in the fact that many human studies are small, short-term, and frequently funded by manufacturers, which, while not inherently invalidating, necessitates greater scrutiny. Moreover, while NMN boosts NAD+ levels, the extent to which this translates into clinically meaningful improvements in human healthspan or lifespan, especially in healthy individuals, is still largely unproven. The specific dosages and formulations optimal for humans also remain unclear, with current supplement marketing often preceding definitive scientific guidance.
For individuals seeking to optimise their healthspan, relying on NMN supplementation based on current human evidence is premature. While the mechanistic basis is sound, and animal data compelling, robust, independent human trials demonstrating significant, broad health benefits are lacking. Lifestyle interventions, such as a balanced diet, regular exercise, adequate sleep, and stress management, have far more extensive and consistent evidence for promoting health and longevity. These foundational practices are known to support NAD+ levels and overall cellular health through various mechanisms. Those considering NMN should be aware of the limited human data, the potential for commercial bias, and the significant cost of supplementation, weighing these against the established benefits of traditional health practices.
Vitaei verdict
Overstated by the evidence. While NMN shows promise in animal models and is safe in humans, robust, independent human clinical data for broad anti-ageing effects are largely absent.